Female Reproductive System Adnexal Neoplasm

cancer family

Identifier: CI-CAN-00000180
Entity page: /cancer/female-reproductive-system-adnexal-neoplasm ↗
Edges: 3,837

Neighbours: 15 genes15 drugs10 trials
Drawn: 40 of 40 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Female Reproductive System Adnexal Neoplasm approved for …APPROVED_FORderived9 of 9
← approved for	Carboplatinsmall molecule FDA (US) · approved · 2025-08-08 · As part of a combination regimen, for the initial treatment of advanced ovarian carcinoma.	—	approved	Ovarian Carcinoma	1	Regulatory	openfda	graph →
← approved for	Carboplatinsmall molecule

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

BRCA1 Mutation Olaparib36 active / 88 trials
Curatedlevel Asensitivity· support 4civicObservedBRCA1 altered in 12% (37 / 316 cases)no approval record in this cancercontext: Malignant Ovarian Neoplasm
BRCA1 Mutation Rucaparib2 active / 16 trials
Curatedlevel Asensitivity· support 4civicObservedBRCA1 altered in 12% (37 / 316 cases)no approval record in this cancercontext: Malignant Ovarian Neoplasm
BRCA2 Mutation Rucaparib2 active / 16 trials
Curatedlevel Asensitivity· support 4civicObservedBRCA2 altered in 11% (34 / 316 cases)no approval record in this cancercontext: Malignant Ovarian Neoplasm
BRCA2 Mutation Olaparib36 active / 88 trials
Curatedlevel Asensitivity· support 3civicObservedBRCA2 altered in 11% (34 / 316 cases)no approval record in this cancercontext: Malignant Ovarian Neoplasm
BRCA1 Mutation Niraparib22 active / 70 trials
Curatedlevel Asensitivity· support 1civicObservedBRCA1 altered in 12% (37 / 316 cases)no approval record in this cancercontext: Ovarian Carcinoma
BRCA2 Mutation Niraparib22 active / 70 trials
Curatedlevel Asensitivity· support 1civicObservedBRCA2 altered in 11% (34 / 316 cases)no approval record in this cancercontext: Ovarian Carcinoma
BRCA1 Mutation Platinum Compound0 active / 0 trials
Curatedlevel Bsensitivity· support 2civicObservedBRCA1 altered in 12% (37 / 316 cases)no approval record in this cancercontext: Ovarian Carcinoma
BRCA2 Mutation Platinum Compound0 active / 0 trials
Curatedlevel Bsensitivity· support 2civicObservedBRCA2 altered in 11% (34 / 316 cases)no approval record in this cancercontext: Ovarian Carcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Female Reproductive System Adnexal Neoplasm altered in cohorts of …ALTERED_INderived15 of 117show all (up to 200)
← altered in cohorts of	TP53 483 / 603 cases (80 %) · ssm · TCGA-OV · largest of 6 cohorts	—	—	Ovarian Serous Cystadenocarcinoma	6	Observed	gdc	graph →
← altered in cohorts of	MYC 455 / 603 cases (75 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	FAM135B 449 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	POU5F1B 449 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ACTRT3 447 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ADCY8 446 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AGO2 446 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LRRC34 446 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MYNN 446 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PTK2 446 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	GPR20 445 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	GSDMC 445 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LRATD2 445 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LRRC31 445 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LRRIQ4 445 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →

Female Reproductive System Adnexal Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 236show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 343 trials (71 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adnexal Neoplasm	343	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 312 trials (59 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adnexal Neoplasm	312	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 189 trials (74 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adnexal Neoplasm	189	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 100 trials (24 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adnexal Neoplasm	100	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 98 trials (44 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adnexal Neoplasm	98	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 95 trials (14 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adnexal Neoplasm	95	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 90 trials (20 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adnexal Neoplasm	90	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 88 trials (36 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adnexal Neoplasm	88	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 86 trials (25 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adnexal Neoplasm	86	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 77 trials (19 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adnexal Neoplasm	77	Observed	clinicaltrials	graph →
→ investigated in trials for	Niraparibsmall molecule 70 trials (22 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adnexal Neoplasm	70	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 48 trials (4 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adnexal Neoplasm	48	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 43 trials (1 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adnexal Neoplasm	43	Observed	clinicaltrials	graph →
→ investigated in trials for	Chemotherapy 38 trials (13 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adnexal Neoplasm	38	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 36 trials (17 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adnexal Neoplasm	36	Observed	clinicaltrials	graph →

Female Reproductive System Adnexal Neoplasm studied in …STUDIED_INderived10 of 3,475show all (up to 200)
→ studied in	NCT01242072Phase 1 · completed Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies · condition mapped CURATED_EXACT · 3,475 trials mapped (950 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 3,475 trials mapped (950 active)	—	—	Fallopian Tube Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 3,475 trials mapped (950 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 3,475 trials mapped (950 active)	—	—	Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 3,475 trials mapped (950 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03348631Phase 2 · active not recruiting Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 3,475 trials mapped (950 active)	—	—	Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05051722recruiting Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer · condition mapped CURATED_EXACT · 3,475 trials mapped (950 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05128825Phase 2 · recruiting A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 3,475 trials mapped (950 active)	—	—	Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05287451NA · recruiting Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study · condition mapped CURATED_EXACT · 3,475 trials mapped (950 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · condition mapped CURATED_BROADER · 3,475 trials mapped (950 active)	—	—	Fallopian Tube Carcinoma	1	Observed	clinicaltrials	graph →